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Abstract
Bolus injections of adenosine and the A2A adenosine receptor (AR) selective
agonist (regadenoson) are used clinically as a substitute for a stress test in
people who cannot exercise. Using isolated tissue preparations, our lab has
shown that coronary flow and cardiac effects of adenosine are mostly regu-
lated by the AR subtypes A1, A2A, and A2B. In this study, we used ultrasound
imaging to measure the in vivo effects of adenosine on coronary blood flow
(left coronary artery) and cardiac function in anesthetized wild-type, A1
knockout (KO), A2AKO, A2BKO, A3KO, A1, and A3 double KO (A1/3 DKO)
and A2A and A2B double KO (A2A/2B DKO) mice in real time. Echocardio-
graphic and Doppler studies were performed using a Visualsonic Vevo 2100
ultrasound system. Coronary blood flow (CBF) baseline data were obtained
when animals were anesthetized with 1% isoflourane. Diameter (D) and veloc-
ity time integral (VTI) were measured on the left coronary arteries
(CBF = ((p/4) 9 D2 9 VTI 9 HR)/1000). CBF changes were the highest
within 2 min of injection (about 10 mg/kg). Heart rate, cardiac output, and
stroke volume were measured by tracing the left ventricle long axis. Our data
support a role for the A2 AR in CBF and further support our conclusions of
previous studies from isolated tissues. Adenosine-mediated decreases in car-
diac output and stroke volume may be A2B and/or A3 AR-mediated; however,
the A1 and A2 ARs also play roles in overall cardiac function. These data fur-
ther provide a powerful translational tool in studying the cardiovascular
effects of adenosine in disease states.
Introduction
Intravenous adenosine injection has been used clinically
to treat surgical and nerve pain (Sjolund et al. 2001), pul-
monary hypertension (Fullerton et al. 1996; Ng et al.
2004), and paroxysmal supraventricular tachycardia (Ran-
kin et al. 1992; Chronister 1993; Lozano et al. 1995).
However, the main use of adenosine is for myocardial
perfusion imaging in patients who cannot exercise. There
are four adenosine receptor (AR) subtypes, A1, A2A, A2B,
ª 2016 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
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and A3, and all have demonstrated a role in regulating
coronary blood flow (CBF) and cardiac function. Studies
from our lab and others have demonstrated that the A2A
AR is the predominant AR in the coronary circulation,
with the A2B AR playing a complimentary role; the A1
and A3 ARs play only modulating roles in CBF regulation.
Regarding their roles in cardiac function, in general, only
the A1 AR mediates the negative dromotropic and chron-
otropic properties of adenosine, while the A1, A2A, and
A2B ARs all mediate inotropic properties in some way
depending on the species and pathological situation.
There are very few reports on the role of the A3 AR in
cardiac function due to its low expression level.
Because of the availability of many transgenic strains,
mice have become one of the most widely used models in
medical research. However, their small size makes it very
difficult to measure the cardiac function, especially CBF,
in live animals. Ultrasound measurement of CBF and car-
diac function has been routinely used in humans, and this
noninvasive method has also been used in measuring
mouse cardiac function in recent years (Katz et al. 2011).
Since previous functional studies of ARs have been mostly
conducted ex vivo or in vitro using pharmacological
tools, the specificity of adenosine analogs to these ARs
and their translational relevance have always come into
question. Therefore, using genetic AR knockout (KO)
mice, we sought to confirm previous findings in isolated




All the AR KO and DKO mice were obtained from Dr.
Stephen Tilley, University of North Carolina Chapel Hill,
with the A2A AR KO mice originating from Dr. Catherine
Ledent of Universite Libre de Bruxelles, Brussels, Belgium.
All KO and DKO mice were of the C57BL/6 (WT)
background.
Assessment of echocardiography and
coronary blood flow Doppler measurement
Each mouse was anesthetized in an induction chamber
with inhalant isofluorane at 3% in 100% oxygen. When
fully anesthetized, the mouse was transferred to dorsal
recumbency, placed on a heated imaging platform, and
maintained at 1–1.25% isofluorane for the duration of
the experiment. The hair of the mouse chest wall was
carefully removed, and warm electrode gel was applied to
the limb leads, allowing for an electrocardiogram and res-
piration rate to be recorded during ultrasound imaging.
A rectal probe was used to monitor body temperature.
Ultrasound images were acquired using an MS550D
transducer (22–55 MHz) on a Vevo2100 Imaging System
(Visual Sonics, Toronto, Ontario, Canada). Placing the
transducer to the left of the sternum allowed us to obtain
images of the aortic outflow tract, the apex of the heart,
and the left ventricle along its longest axis (i.e., long-axis
B-mode images). Once all long-axis B-mode images were
attained, the transducer was rotated 90 degrees to acquire
short-axis B-mode images at the mid-papillary muscle
level, then moved up until the left coronary artery (LCA)
was visible for vessel size measurement (Fig. 1A). The
transducer was rotated back to the long-axis parasternal
view with the probe lateralized and the ultrasound beam
anteriorly tilted. In this image window, the entire LCA,
from the aortic sinus to the distal branch site, could be
visualized using color Doppler echocardiography. The
course of the LCA was typically parallel to the Doppler
beam, which also facilitates Doppler measurements with-
out any angle correction. The system was then switched
to pulse-wave Doppler mode with a gate size of 0.65 mm.
Coronary flow signals were identified on the Doppler
spectral display by flow toward the probe peaking in early
diastole, followed by decay, and being minimal during
systole as illustrated in Figure 1B. Bolus adenosine injec-
tion (0.2 mg/mouse; approximately 10 mg/kg) was made
through the femoral vein. The dosage was chosen based
upon previous studies (Zhao et al. 2000; Koeppen et al.
2009). The high dose was chosen because we want to
make sure that all adenosine receptors get activated and
knowing that adenosine has a short half-life which will
reduce its effect over the period of our measurement. The
blood flow velocity was measured using Doppler principle
to directly measure the flow motion (pulsed-wave Dop-
pler mode, PW-mode). It will not pick up tissue motion.
Measuring the size of coronary arteries using basic ultra-
sound mode (B-mode, or bright mode) will not pick up
any flow motion. They do not interfere with each other.
The flow velocity measurements were made at the same
vessel site at baseline and during adenosine-induced
hyperemia (Fig. 1C). Measurements were averaged from
three consecutive cardiac cycles.
Coronary blood flow was calculated using the following
formula: FlowCBF (mL/min) = ((p/4) 9 D
2 9 VTI 9
HR)/1000 (Katz et al. 2011) where D is the internal coro-
nary diameter (in mm) measured in B-mode ultrasound
images, VTI is the velocity–time–integral (in mm), or area
under the curve of the Doppler blood flow velocity tracing,
and HR is heart rate. Coronary flow reserve (CFR) =
CBFadenosine/CBFbaseline where CBFadenosine is the peak coro-
nary flow measured after 0.2 mg adenosine (in 500 lL sal-
ine) femoral vein intravenous injection. The peak CBF was
usually reached within 1½ mins after injection.
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After peak CBF was reached, the effect of adenosine on
cardiac function and coronary artery size were measured
again.
Statistical analysis
One-way ANOVA and Bonferroni’s multiple comparison
post test was used to compare between mouse groups in
all data set.
Results
All baseline CBF and cardiac function parameters are
presented in Table 1. CBF after adenosine injection and
coronary reserve (CBF after adenosine injection/baseline
CBF) are presented in Figure 2. For cardiac functions,
data are presented as % changes (increase or decrease)
after adenosine injection, except ejection fraction (EF),
which was its original value after adenosine injection
(Fig. 3). Comparisons were made between mouse
groups.
Coronary flow
Baseline coronary flow was not different between all of
the AR KOs and the wild-type (WT) mice (Table 1),
although A1/3 DKO mice showed higher baseline flow
than A1 KO mice. Only the A2A KO, A2B KO, and A2A/2B
DKO mice demonstrated significant differences from WT
in response to bolus adenosine injection (Fig. 2A), while
coronary reserve in all single and DKO mice was signifi-
cantly reduced except when A1 KO mice (Fig. 2B) were
compared to WT.
Heart rate
Baseline HR was not different between all groups of mice
(Table 1). There were two phases of HR responses after
bolus injection of adenosine. Initially, HR decreased
instantly (for the first 20–30 sec) and significantly in all
mice (from about 470 bpm to 150 bpm), except in A1
KO and A1/3 DKO mice. Complete atrioventricular (AV)
block was also observed in most mice except A1 KO and
A1/3 DKO mice. HR increased during the second phase.
When compared between groups by their % changes in
HR at the second phase, only A1/3 DKO mice demon-
strated significantly less change from WT, A2A KO, and
A2B KO mice (Fig. 3A).
Stroke volume
Baseline stroke volume (SV) was significantly lower in A1
KO and A2A/2B DKO mice (Table 1). Bolus adenosine
injection induced a significant decrease in SV in WT
mice. When compared between groups, only A3 KO and
A1/3 DKO mice were significantly different from other
groups (Fig. 3C).
Figure 1. Sample ultrasound images for (A) size of coronary artery;
(B) baseline pulse wave Doppler; (C) adenosine-induced increase in
pulse wave Doppler.
ª 2016 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
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Cardiac output
Baseline cardiac output (CO) decreased significantly in A1
KO, A2B KO, and A2A/2B DKO mice (Table 1) when com-
pared to WT mice. Bolus adenosine injection decreased
CO. When compared between groups, the changes in CO
in A3 KO and A1/3 DKO mice were significantly lower
than WT and A2A KO mice (Fig. 3B).
Ejection fraction
Compared to WT mice, baseline EF decreased only in
A2A/2B DKO mice (Table 1). After bolus adenosine
injection, EF increased in WT (from 55.37  7.49% to
65.18  12.79%), and the EF of A2A KO, A2B KO, and
A2A/2B DKO mice was lower than WT mice after adeno-
sine injection (Fig. 3D).
End-diastolic volume
There was no difference in baseline end-diastolic volume
(EDV) between all mice (Table 1). After adenosine injec-
tion, EDV decreased. However, EDVs decreased less in A3
KO and A1/3 DKO mice after adenosine injection when
compared to other mouse groups. (Fig. 3E).
End-systolic volume
Similar to EDV, there is no difference in baseline end-sys-
tolic volume (ESV) between all mice (Table 1), and ESV
decreased after adenosine injection (Fig. 3F). When com-
pared between mouse groups, the decrease in ESV was
less in A2B KO, A3 KO, and A1/3 DKO mice when com-
pared to WT mice. The decrease in ESV in A3 KO and
A1/3 DKO mice was also significantly less than in A1 KO
mice, and the decrease in A1/3 DKO mice was less when
compared to A2A KO mice (Fig. 3F).
Discussion
This is the first in vivo study looking into both the car-
diac and coronary flow responses of adenosine in all
existing AR KO mice (single and double). Although this
has not been done in all four AR KOs, the authors have
done isolated mouse coronary artery study in A2A KO
mice (Teng et al. 2008). In addition, several studies from
our lab and others using isolated mouse hearts have
clearly demonstrated AR-mediated coronary vasodilation


















0.31  0.099 0.21  0.07 0.30  0.08 0.27  0.05 0.31  0.07 0.27  0.08 0.37  0.10 &
Heart rate (BPM) 452  32 444  29 484  68 420  46 442  18 466  89 498  62
Stroke volume
(lL)
36.72  7.61 24.93  3.56* 31.13  8.53 28.12  5.11 33.52  3.53 22.94  4.71* 32.06  7.88
Cardiac output
(mL/min)
15.97  3.13 10.98  1.14* 14.66  2.93 11.87  1.65* 14.82  1.63 10.56  2.21*$% 15.70  3.27 &+
Ejection fraction
(%)
55.37  7.49 46.01  5.70 46.49  8.34 54.57  7.57 51.67  4.2 43.15  5.82*@ 48.18  6.74
EDV (lL) 66.55  12.02 57.48  8.37 62.75  11.56 49.98  6.81 65.11  7.11 53.15  7.88 67.94  20.67
ESV (lL) 29.82  8.12 31.91  6.40 36.34  11.78 24.39  4.32 31.59  5.51 30.21  5.30 35.89  14.33
*Significantly different from WT, &A1KO,
$A2AKO,
@A2BKO,
%A3KO, +A2A2BDKO; P < 0.05.
Figure 2. Coronary blood flow (A) and coronary reserve after
bolus adenosine i.v. injection (B) for adenosine knockout mice and
their wild type control. *Significantly different from WT; #A1KO.
P < 0.05.
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in mice (Morrison et al. 2002; Teng et al. 2008; Headrick
and Lasley 2009; Sanjani et al. 2011). The technique we
used here is not new, though rarely used in measuring
mouse coronary artery flow due to technical difficulty.
Furthermore, previous studies mostly focused on one or
two strains of adenosine receptor KO mice. In this study,
using all four adenosine KO mice give us a unique
prospective of the cardiac and coronary effects of adeno-
sine in live animals, which has never been done in the
past. The baseline coronary flow was well maintained in
all KO mice in this study; however, their responses to
adenosine bolus injection were not the same. As expected,
the coronary flow responses to adenosine were lower in
A2A KO, A2B KO, and A2A/2B DKO mice compared to
WT mice (Fig. 2A), which supports our and others
ex vivo model findings that both A2A and A2B ARs play
major roles in adenosine-induced coronary vasodilation.
Interestingly, except for A1 KO mice, all other KO mice
showed decreases in coronary reserve (Fig. 2B). The
major determinant for CBF is oxygen demand of the
heart; therefore, the effect of adenosine on HR, contractil-
ity, and wall tension can all possibly be affecting CBF and
Figure 3. The effects of bolus adenosine i.v. injection on heart rate (A), cardiac output (B), stroke volume (C), ejection fraction (D), end




+A2A/2B-DKO. P < 0.05.
ª 2016 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
the American Physiological Society and The Physiological Society.
2016 | Vol. 4 | Iss. 11 | e12818
Page 5
B. Teng et al. Coronary Flow in Adenosine Receptor Knockouts In Vivo
reserve. A1/3 DKO mice demonstrated relatively higher
baseline CBF (Table 1) when compared to other groups
(except A1 KO mice), indicating possibly higher baseline
cardiac work. However, ventricular pressure was not mea-
sured in our experiments (hence no index of cardiac
work); therefore, it is difficult to interpret these results
and the physiological significance of these findings. Nev-
ertheless, the importance of A2A and A2B ARs in CBF reg-
ulation was confirmed in vivo in mice.
In addition to coronary circulation, all four ARs were
also found in cardiac tissue (Lasley and Smart 2001; Mor-
rison et al. 2006). In isolated heart tissue, adenosine pro-
duces a negative inotropic effect in atrial and ventricular
myocardium (Dobson 1983; Belardinelli et al. 1989). The
A1 AR was found to exert a negative inotropic effect by
inhibiting b-adrenergic effects, while the A2A AR modu-
lated the b-adrenergic inhibiting effect of the A1 AR (Tikh
et al. 2006; Chandrasekera et al. 2010). The A2B AR
demonstrated moderate direct, positive inotropic effects
(Chandrasekera et al. 2010). Therefore, it is not surprising
to observe lower baseline SV and CO in A2A/2B DKO mice
(Table 1). Future studies on the cross-talk between ARs
and b-adrenergic receptors are warranted. However, it is
surprising that the baseline SV and CO also decreased in
A1 KO mice. Previous studies in isolated heart experi-
ments in A1 KO mice did not show baseline changes in
contractility when compared to WT mice (Morrison et al.
2000, 2004; Tawfik et al. 2006). The reason for this dis-
crepancy is not clear. However, we speculate that this
decrease in baseline SV and CO in A1 KO mice may be
due to compensatory changes in another vascular system
(s) that affects their hemodynamic regulation. For
instance, upregulation of the A2B AR was reported from
our lab in the mesenteric arteries of A1 KO mice (Teng
et al. 2013), but their influence on regional blood flow
may affect systemic circulation, and this has not been
studied. Furthermore, our previous ex vivo studies on
coronary flow regulation in A2A and A2B KO mice
demonstrated up-regulation of either AR, if the other was
genetically deleted (Teng et al. 2008; Sanjani et al. 2011).
Therefore, compensatory responses in these KO mice can-
not be ignored. Although the A3 AR has been proven to
protect cardiac function in ischemia-reperfusion injury
(Cerniway et al. 2001; Harrison et al. 2002), it did not
seem to directly affect cardiac contractility in isolated
heart preparations (Harrison et al. 2002; El-Awady et al.
2013) that measured left ventricular function. However,
the A3 AR induces positive inotropy in atrial tissue
through regulating the ryanodine receptor and calcium/
calmodulin-dependent kinase II (CaMKII) (Yuan et al.
2008). Furthermore, A3 AR overexpressing mice also
demonstrated an increase in left atrium size, suggesting
increased ESV (Fabritz et al. 2004). Based upon the
Frank–Starling mechanism, an increase in right atrium
contraction increases preload (i.e., end diastolic volume)
and subsequently increases SV. This is supported by our
study where A3 KO and A1/3 DKO mice were the only
groups with reduced EDV and ESV changes (Fig. 3E and F)
that were reflected in the reduction in SV and CO (Fig. 3B
and C).
A significant decrease in HR after application of adeno-
sine was observed in ex vivo animal models in our lab
and others and is well documented as an A1 AR-mediated
effect, including both direct (shortening action potential)
and indirect (inhibiting b-adrenergic effect) (Headrick
et al. 2000; Lerman et al. 2001; Dhalla et al. 2003; Kirch-
hof et al. 2003; Mustafa et al. 2009) effects. In healthy
subjects, bolus injection of adenosine briefly reduces heart
rate and induces AV block, followed by a more sustained
increase in HR (Sylven et al. 1989), while infusion of
adenosine induces a dose-dependent increase in HR
(Biaggioni et al. 1986) that may be due to an adenosine-
induced decrease in blood pressure (reflex tachycardia). A
previous in vivo study in anesthetized mice also demon-
strated a similar biphasic HR response after bolus adeno-
sine injection (Koeppen et al. 2009). Because of the
significant adenosine-induced decrease in blood pressure
found in this study, it is reasonable to presume that the
secondary increase in HR (about 30 sec after injection)
after the initial decrease is due to reflex tachycardia. In
our study, we observed the same biphasic changes in HR
after bolus adenosine injection in all mouse strains except
with A1 AR deletion (A1 KO and A1/3 DKO), which only
shows that HR increases (the second phase) about 30 sec
after the injection. Surprisingly, A3 AR deletion (A3 KO
and A1/3 DKO mice) did not show the second phase of
HR increase (Fig. 3A). This is the first report of such a
finding in A3 KO mice. A3 AR overexpressing mice
showed profound resting bradycardia, AV block, and
incessant bradycardia–tachycardia syndrome, but return
to normal rhythm during exercise (Fabritz et al. 2004).
Unlike the A1 AR, its effect was not b-adrenergic medi-
ated and is possibly mediated through Rho kinase (Fab-
ritz et al. 2004). A previous in vivo study of intracerebral-
ventricular injection of adenosine analogs suggested that
there is a population of A3 ARs present in the CNS whose
activation induces a decrease in blood pressure with no
change in HR (Stella et al. 1998). Since it is still unclear
how the central and peripheral mechanisms of adenosine
receptor-dependent regulation of blood pressure and HR
act in concert, further studies are needed to clarify the
role of ARs in HR regulation.
Another interesting finding in this study is the influ-
ence of the A2A and A2B ARs on EF. In a mathematic
model, EF equals to SV divided by EDV and is an impor-
tant indicator for cardiac function. In all the KO mice we
2016 | Vol. 4 | Iss. 11 | e12818
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studied, A2A/2B DKO mice were the only KO model that
showed significantly lower EF than WT control (Table 1).
Despite a reduction in SV and CO after adenosine injec-
tion, EF increased to 65.19  12.79% (Fig. 3D) in WT
mice from a baseline of 55.37  7.49% (Table 1). After
adenosine injection, only A2A KO, A2B KO, and A2A/2B
DKO mice demonstrated significant differences in EF
(45.85  13.90, 41.98  12.40, and 42.21  8.65%, res-
pectively) when compared to WT (Fig. 3D). In isolated
heart studies, both the A2A and A2B AR were found to
increase contractility (Dobson 1983; Tikh et al. 2006;
Chandrasekera et al. 2010). However, increases in HR, like
we observed in this study after adenosine injection, has
been shown to decrease SV, EDV, and ESV due to
decreases in ventricle refilling time (Erbel et al. 1984).
Combined effects of increased inotropy and reduced ven-
tricle refilling time (increase in HR) may create stiffness
in the ventricles (i.e., increasing end-diastolic pressure
without increasing EDV). Furthermore, A2A AR stimula-
tion has been shown to decrease venous resistance
(Nekooeian and Tabrizchi 1996, 1998), possibly reducing
venous return and reducing EDV further, increasing EF.
However, the A3 AR (and possible the A2B AR) seems to
play a prominent role in adenosine-induced EDV and
ESV reduction by constricting the left atrium as men-
tioned above (Fig. 3E and F). It becomes very difficult to
interpret the in vivo data in relation to possible mecha-
nism(s) of A2A and A2B AR-mediated improvement in
EF. Further studies are needed to address this paradox
using isolated tissues with molecular approach.
In conclusion, using KO mice, we confirmed that both
the A2A and A2B ARs are involved in adenosine-induced
increases in CBF. Bolus injection of adenosine at a dosage
of 0.2 mg/mouse (about 10 mg/kg) decreased CO and SV
and may be A2B and/or A3 AR-mediated; however, the A1
and A2A ARs also play roles in overall cardiac function,
such as in HR and EF regulation. These data further pro-
vide evidence that the combination of AR KO mice and
the use of the Doppler/ultrasound technique to measure
cardiac and coronary function in live animals is a power-
ful translational tool in studying the cardiovascular effects
of adenosine, especially in disease states, in the future.
Limitations of the study
The resolution of Vevo system is 30 lm while the size of
the mouse left coronary artery is about 200 lm measured
by the system. The standard errors of coronary artery
were quite large in some cases. Therefore, it is hard to
definitively state small changes. To simplify, some previ-
ous studies only used VTI or max flow as an indicator of
coronary flow to calculate the reserve (Wikstrom et al.
2005, 2008), which is not suitable in our study that
requires actual flow measurement to compare baseline
blood flow. Nevertheless, in general, the baseline coronary
artery size is about 200 and 220–230 lm after adenosine
injection in KO mice. The difference is smaller than the
resolution stated. Therefore, we cannot state with cer-
tainty the adenosine effect on size of the coronary artery.
Although all AR KO mice we studied here have been in
existence for some time, not all of them have their car-
diovascular phenotype evaluated. In few reports, only A2A
KO mice have been shown to be hypertensive with some
neurological disorder (Ledent et al. 1997). To the best of
our knowledge, there is no report of other AR KO mice
demonstrating baseline blood pressure deviation from
WT. Since blood pressure affects cardiac work and subse-
quent coronary blood flow, the lack of information on
blood pressure in our study (our current ultrasound
equipment setting does not allow us to measure blood
pressure simultaneously) did limit our full interpretation
of the cardiovascular function (s) of adenosine. Neverthe-
less, the utilization of all AR KOs still provides valuable
validation of previous ex vivo study and some insight into
possible future pharmacological studies in relation to the
cardiovascular effects of adenosine with potential for
translational studies.
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